Why the study?
Recent significant advancements in pharmacological and invasive therapies are transforming the management of hypertrophic cardiomyopathy, alongside ongoing trials of investigational therapies.
This narrative review summarizes recent advancements in the management of hypertrophic cardiomyopathy, highlighting emerging therapies such as cardiac myosin inhibitors, radiofrequency ablation, and gene editing.
Answers are grounded in this paper and cite their sources.
Emerging HCM therapies require prospective validation before adoption; leaves open questions on durability and safety in routine care.
Hypertrophic cardiomyopathy is the most prevalent inherited cardiac condition, distinguished by an autosomal dominant inheritance pattern. Diagnosis can be achieved through echocardiography, cardiac magnetic resonance imaging, and genetic testing. Recently, significant advancements have occurred in pharmacological and invasive therapies that are transforming the management of hypertrophic cardiomyopathy, including the introduction of cardiac myosin inhibitors, radiofrequency ablation, and gene editing. Additional trials are being conducted on investigational therapies, with the results anticipated in the near future. This review aims to provide a concise overview of both currently approved and investigational treatments for hypertrophic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Ogurek et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: